Skip to main content
SpringerLink
Log in

Bimonthly 48-h Leucovorin and 5-Fluorouracil-Based Regimens in Advanced Colorectal Cancer

  • Chapter
Fluoropyrimidines in Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 201 Accesses

Abstract

5-Fluorouracil (5-FU) has been the mainstay of systemic therapy for metastatic colorectal cancer since its introduction into clinical practice more than four decades ago and remains the agent of choice in the treatment of this malignancy. However, objective responses are observed in less than 20% of patients treated with single-agent 5-FU administered as a bolus, with a median survival of less than 9 mo.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425–32.

    PubMed  CAS  Google Scholar 

  2. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301–8.

    Google Scholar 

  3. hansen RM, Quebbeman E, Anderson T. 5-Fluorouracil by protracted venous infusion. A review of current progress. Oncology 1989; 46: 245–50.

    Article  PubMed  CAS  Google Scholar 

  4. Hansen RM, Ryan L, Anderson T, et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. JNatl Cancer Inst 1996; 88: 668–74.

    Article  CAS  Google Scholar 

  5. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995; 13: 1303–11.

    PubMed  CAS  Google Scholar 

  6. Rougier PH, Paillot B, Laplanche A, et al. End results of a multicenter randomized trial comparing 5-FU in continuous systemic infusion (CI) to bolus administration (B) in measurable metastatic colorectal cancer. Proc Am Soc Clin Oncol 1992; 11: 163.

    Google Scholar 

  7. Mori A, Bertoglio S, Guglielmi A, et al. Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 1993; 33: 179–80.

    Article  PubMed  CAS  Google Scholar 

  8. Evans RM, Laskin JD, Hakala MT. Effects of excess folates and deoxyinosine on activity and site of action of 5-fluorouracil. Cancer Res 1981; 41: 3288–95.

    PubMed  CAS  Google Scholar 

  9. Houghton JA, Maroda SJ, Philips JO, Houghton PJ. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts fo human colorectal adenocarcinoma in mice. Cancer Res 1981; 41: 144–9.

    PubMed  CAS  Google Scholar 

  10. Rustum YM, Trave F, Zakrzewski SF, et al. Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr 1987; 5: 165–70.

    PubMed  Google Scholar 

  11. Petrelli N, Douglass HO Jr, Herrera L, et al. for the Gastrointestinal Tumor Study Group. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419–26.

    PubMed  CAS  Google Scholar 

  12. Poon MA, OConnell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407–18.

    PubMed  CAS  Google Scholar 

  13. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903.

    Google Scholar 

  14. Sobrero AF, Aschele C, Guglielmi AP, et al. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 1993; 85: 1937–44.

    Article  PubMed  CAS  Google Scholar 

  15. de Gramont A, Krulik M, Cady J, et al. High dose-folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988; 24: 1499–1503.

    Article  PubMed  Google Scholar 

  16. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997a; 15: 808–15.

    PubMed  Google Scholar 

  17. Beerblock K, Rinaldi Y, André T, et al. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d’Etude et de Recherche sur les Cancers de l’Ovaire et Digestifs (GERCOD). Cancer 1997; 79: 1100–15.

    Article  PubMed  CAS  Google Scholar 

  18. Tournigand C, de Gramont A, Louvet C, et al. for the GERCOR. A simplified bimonthly regimen with leucovorin and 5FU for metastatic colorectal cancer. Proc Am Soc Clin Oncol 1998; 17: 274.

    Google Scholar 

  19. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998a; 25(suppl 5)4–12.

    Google Scholar 

  20. Becouarn Y, Ychou M, Ducreux M, et al. A phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998; 8: 2739–44.

    Google Scholar 

  21. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998; 9: 105–8.

    Article  PubMed  CAS  Google Scholar 

  22. Lévi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of five-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 9 (29A): 1280–4.

    Article  Google Scholar 

  23. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998b; 9: 1053–71.

    Article  PubMed  CAS  Google Scholar 

  24. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–47.

    PubMed  Google Scholar 

  25. de Gramont A, Gastiaburu J, Tournigand C, et al. Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 hour infusion in pretreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 1994; 13: 220.

    Google Scholar 

  26. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5 fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997b; 33: 214–19.

    Article  PubMed  Google Scholar 

  27. André T, Louvet C, Raymond E, Tournigand C, de Gramont A. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998; 9: 1–3.

    Article  Google Scholar 

  28. André T, Louvet C, Maindrault-Goebel F, et al. on behalf of GERCOR. CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur J Cancer 1999; 35: 1343–7.

    Article  PubMed  Google Scholar 

  29. Maindrault-Goebel F, Louvet C, André T, et al. for the GERCOR. Oxaliplatin added to the simplified bimonthly leucovorin and 5 fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 1999a; 35: 1338–42.

    Article  PubMed  CAS  Google Scholar 

  30. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, for the GERCOR. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX7). Proc Am Soc Clin Oncol 1999b; 18: 265.

    Google Scholar 

  31. de Gramont A, Maindrault-Goebel F, Louvet C, et al. for the GERCOR. Evaluation of oxaliplatin dose-intensity with the bimonthly 48h leucovorin and 5 fluorouracil regimens (FOLFOX) in pretreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: 265a.

    Google Scholar 

  32. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitor: topotecan and irinotecan. Cancer Treat Res 1994; 20: 73–96.

    Article  CAS  Google Scholar 

  33. Ducreux M, Ychou M, Seitz JF, et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with colorectal cancer. J Clin Oncol 1999; 17: 2901–8.

    PubMed  CAS  Google Scholar 

  34. Pitot HC, Wender DB, OConnell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 5: 2910–19.

    Google Scholar 

  35. Shimada Y, Rothenberg M, Hilsenbeck SG, Burris HA 3rd, Degen D, Von Hoff DD. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase inhibitor, against human tumour colony-forming units. Anticancer Drugs 1994; 5: 20–6.

    Article  Google Scholar 

  36. Rougier P, Bugat R, Douillard Y, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251–60.

    PubMed  CAS  Google Scholar 

  37. Cunningham D, Pyrhonen S, James RD, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413–8.

    Article  PubMed  CAS  Google Scholar 

  38. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1407–12.

    Article  PubMed  CAS  Google Scholar 

  39. Mullany S, Svingen PA, Kaufmano SH, Erlichman C. Effect of adding the topoisomerase 1 poison 7-ethyl 10-hydroxycamptothecin (SN 38) to 5-fluorouracil and folinic acid in HCT8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharm 1998; 42: 391–99.

    Article  CAS  Google Scholar 

  40. Mabro M, André T, Louvet Carola E, Beerblock K, Krulik M, de Gramont A. Bimonthly leucovorin, 5-fluorouracil infusion and hydroxyurea followed by CPT-11 (FOLFIRI-2) in pretreated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000; 19: 294a.

    Google Scholar 

  41. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041–7.

    Article  PubMed  CAS  Google Scholar 

  42. Tournigand C, Achille E, Lledo G, et al. FOLFIRI followed by FOLFOX or FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC). Preliminary results of a randomized phase III study of the GER-COR. ESMO meeting, Hamburg, October 2000.

    Google Scholar 

Download references

Authors
  1. Aimery de Gramont MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christophe Louvet MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Roswell Park Cancer Institute, Buffalo, NY, USA

    Youcef M. Rustum

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

de Gramont, A., Louvet, C. (2003). Bimonthly 48-h Leucovorin and 5-Fluorouracil-Based Regimens in Advanced Colorectal Cancer. In: Rustum, Y.M. (eds) Fluoropyrimidines in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-337-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-337-8_11

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-274-2

  • Online ISBN: 978-1-59259-337-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation